EMERYVILLE, Calif., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The application was evaluated based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named-patient treatment option The Regenerative Medicine Advanced Therapies ...
Patients with stiff person syndrome are one step closer to having access to a new treatment. Kyverna Therapeutics’ new drug, KYV-101, has been designated by the U.S. Food and Drug Administration (FDA) ...
The investigational therapy will be used in Kyverna's KYSA-5 Phase 1/2 open-label, multicenter study to evaluate KYV-101 in adult patients with diffuse cutaneous systemic sclerosis (scleroderma) This ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A patient with lupus nephritis who received KYV-101 ...
Currently in the Phase 1 trial for refractory lupus nephritis (LN, lupus-related kidney disease in which people do not respond to first-line immunosuppressive drugs or quickly relapse after remission) ...
If you've already heard about FASTag and wondered what Know Your Vehicle (KYV) means, you're not alone. KYV is a new step introduced to make sure your vehicle and your FASTag match up correctly. It's ...
EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results